Sanofi (FRA:SNW)
Germany · Delayed Price · Currency is EUR | Market Cap | 105.00B |
| Revenue (ttm) | 45.74B |
| Net Income (ttm) | 9.13B |
| Shares Out | n/a |
| EPS (ttm) | 7.36 |
| PE Ratio | 11.51 |
| Forward PE | 10.76 |
| Dividend | 3.92 (4.58%) |
| Ex-Dividend Date | May 12, 2025 |
| Volume | 738 |
| Average Volume | 4,479 |
| Open | 86.09 |
| Previous Close | 86.60 |
| Day's Range | 86.09 - 86.62 |
| 52-Week Range | 76.92 - 110.02 |
| Beta | n/a |
| RSI | 61.45 |
| Earnings Date | Oct 24, 2025 |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; influenza, booster, meningitis, and travel and endemic vaccines, that includes hepati... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial StatementsNews
Sanofi's Efdoralprin Alfa Meets All Endpoints In Phase 2 AATD Emphysema Study
(RTTNews) - Sanofi (SNY, SNYNF, SAN.PA) announced positive topline results from the global Phase 2 ElevAATe study evaluating efdoralprin alfa (SAR447537, formerly INBRX-101) in adults with alpha-1 ant...
Press Release: Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study Efdoralprin alfa demonstrated superiority in a head-to-head study versus...
Press Release: Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
Sanofi's Tzield gains faster review for additional diabetes indication from FDA
Sanofi's Tzield could become the first therapy to delay the progression of stage 3 type 1 diabetes. Read more here.
Sanofi: FDA Accepts SBLA For Tzield For Expedited Review
(RTTNews) - Sanofi (SNY) said the FDA has accepted for expedited review the supplemental biologics license application for Tzield to delay the progression of stage 3 type 1 diabetes in adults and pedi...
Press Release: Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program If approved, Tzield would be the first disease-mo...
Press Release: Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedix TM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically mean...
Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
ESMO: AlphaMedix TM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors New AlphaMedix data showed sustained and clinically mean...
Sanofi Reports Superior Protection For Older Adults With High-Dose Influenza Vaccine
(RTTNews) - Sanofi SA (SNY) announced that new data from the FLUNITY-HD study showed its high-dose influenza vaccine significantly reduces the risk of hospitalization in adults aged 65 and older compa...
Press Release: Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose Compared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose...
Press Release: Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi's high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease
On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for Sanofi SA’s (NASDAQ: SNY) Rezurock (belumosudil). The French drug maker ...
Sanofi (SNY) Gets EMA Backing for New Drug for Immune Thrombocytopenia
Sanofi (SNY) Gets EMA Backing for New Drug for Immune Thrombocytopenia
Sanofi and Insmed among winners of EU drug recommendations this week
Sanofi (SNY) Seeks Re-Examination of EU Decision on Rezurock for cGVHD
Sanofi (SNY) Seeks Re-Examination of EU Decision on Rezurock for cGVHD
Press Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant...
Press Release: Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
Sanofi's Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia Recommendation based on LUNA 3 phase 3 study demonstrating rapid and durable platelet response and significant...
Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease Paris, October 17, 2025. The European Medicines Agency's Committee for Medicinal Products for ...
Genzyme Ireland Ltd, the Irish arm of biopharma giant Sanofi, pays out 800m dividend as profits soar to over 328m
The main Irish arm of biopharma giant Sanofi last year paid out dividends of 800m.
EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
CHICAGO , Oct. 16, 2025 /PRNewswire/ -- EVOQ Therapeutics, Inc. (EVOQ), a biotechnology company focused on delivering transformative cures for those living with autoimmune diseases, today announced a ...
Hedge Fund Shah Capital Urges Novavax To Consider Sale Amid Vaccine Rollout Struggles, Sees $5 Billion Potential
Shah Capital is reportedly pressing Novavax Inc. (NASDAQ: NVAX) to consider a sale of the biotech firm, citing continued struggles in the rollout of its COVID-19 vaccine . • NVAX stock is showing exc...
ITM Appoints Annette Breunig as Chief People Officer
Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the appointment of Annette Breunig as Chief Peop...
Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out
Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi.
Sanofi and Orano Med succeed in mid-stage trial for neuroendocrine tumor therapy
Sanofi (SNY) stock is in focus as its AlphaMedix therapy developed with Orano Med succeeds in a mid-stage trial for neuroendocrine tumors. Read more here.